[go: up one dir, main page]

WO2004060270A8 - Compositions and methods for the diagnosis and treatment of tumor - Google Patents

Compositions and methods for the diagnosis and treatment of tumor

Info

Publication number
WO2004060270A8
WO2004060270A8 PCT/US2003/029126 US0329126W WO2004060270A8 WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8 US 0329126 W US0329126 W US 0329126W WO 2004060270 A8 WO2004060270 A8 WO 2004060270A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/029126
Other languages
French (fr)
Other versions
WO2004060270A2 (en
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA002503043A priority Critical patent/CA2503043A1/en
Priority to JP2004564724A priority patent/JP2006516192A/en
Priority to AU2003303144A priority patent/AU2003303144A1/en
Priority to EP03813488A priority patent/EP1578996A4/en
Publication of WO2004060270A2 publication Critical patent/WO2004060270A2/en
Anticipated expiration legal-status Critical
Publication of WO2004060270A8 publication Critical patent/WO2004060270A8/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2003/029126 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor Ceased WO2004060270A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002503043A CA2503043A1 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor
JP2004564724A JP2006516192A (en) 2002-10-18 2003-10-15 Compositions and methods for tumor diagnosis and treatment
AU2003303144A AU2003303144A1 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor
EP03813488A EP1578996A4 (en) 2002-10-18 2003-10-15 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US60/418,988 2002-10-18

Publications (2)

Publication Number Publication Date
WO2004060270A2 WO2004060270A2 (en) 2004-07-22
WO2004060270A8 true WO2004060270A8 (en) 2005-07-14

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029126 Ceased WO2004060270A2 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor

Country Status (5)

Country Link
EP (1) EP1578996A4 (en)
JP (1) JP2006516192A (en)
AU (1) AU2003303144A1 (en)
CA (1) CA2503043A1 (en)
WO (1) WO2004060270A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522999A (en) * 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Methods and compositions for treating cancer
WO2003083078A2 (en) 2002-03-28 2003-10-09 Bristol-Myers Squibb Company Novel human cell surface protein with immunoglobulin folds, bgs-19
EP1576096A4 (en) * 2002-04-23 2007-05-23 Univ Georgia Res Found VB N-ACETYLGLUCOSAMINYLTRANSFERASE CODING SEQUENCE, RECOMBINANT CELLS AND RELATED METHODS
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20050186610A1 (en) 2004-02-20 2005-08-25 Yeon-Su Lee Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
PL1791568T3 (en) 2004-08-16 2013-01-31 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
KR20070090156A (en) * 2004-10-13 2007-09-05 에이 앤드 지 파마슈티컬즈, 인코포레이티드 Autocline Growth Factor Receptors and Methods
JP2007008844A (en) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd Monoclonal antibody specifically reacting with septin 2 protein, hybridoma producing the same, cancer detection method and cancer detection kit
DOP2007000015A (en) 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
US8700335B2 (en) * 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2008148072A2 (en) * 2007-05-24 2008-12-04 The Brigham And Women's Hospital, Inc. Disease-associated genetic variations and methods for obtaining and using same
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
EP2334790A1 (en) * 2008-08-27 2011-06-22 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
EP2398902B1 (en) 2009-02-20 2023-10-04 Astellas Pharma Inc. Methods and compositions for diagnosis and treatment of cancer
DK2499161T3 (en) 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6)
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341147B (en) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6.
LT2928921T (en) 2012-12-05 2021-04-26 Novartis Ag Compositions and methods for antibodies targeting epo
EP4614148A3 (en) * 2013-03-15 2025-12-17 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180230540A1 (en) 2015-08-12 2018-08-16 Novartis Ag Methods of treating ophthalmic disorders
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018215780A1 (en) 2017-05-24 2018-11-29 Ammun Limited Use of glutamine synthetase for treating hyperammonemia
CA3113472A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
JP7766904B2 (en) * 2021-06-04 2025-11-11 地方独立行政法人東京都健康長寿医療センター Pharmaceutical composition for treating prostate cancer
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016429A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1311662A2 (en) * 2000-08-24 2003-05-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2001286785B2 (en) * 2000-08-24 2006-08-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
CA2503043A1 (en) 2004-07-22
EP1578996A2 (en) 2005-09-28
AU2003303144A1 (en) 2004-07-29
WO2004060270A2 (en) 2004-07-22
JP2006516192A (en) 2006-06-29
EP1578996A4 (en) 2007-12-19

Similar Documents

Publication Publication Date Title
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003303144

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003813488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2503043

Country of ref document: CA

Ref document number: 2004564724

Country of ref document: JP

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 2003813488

Country of ref document: EP